Satellos Bioscience (TSX:MSCL) Change In Inventory : C$0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Change In Inventory?

Satellos Bioscience's change in inventory for the quarter that ended in Mar. 2024 was C$0.00 Mil. It means Satellos Bioscience's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Satellos Bioscience's change in inventory for the fiscal year that ended in Dec. 2023 was C$0.00 Mil. It means Satellos Bioscience's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Satellos Bioscience's Total Inventories for the quarter that ended in Mar. 2024 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Satellos Bioscience Change In Inventory Historical Data

The historical data trend for Satellos Bioscience's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Change In Inventory Chart

Satellos Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Satellos Bioscience Quarterly Data
	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial										-	-	-	-	-

Satellos Bioscience Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Satellos Bioscience (TSX:MSCL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Satellos Bioscience's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Satellos Bioscience's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Satellos Bioscience's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Satellos Bioscience Change In Inventory Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Satellos Bioscience (TSX:MSCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MSCLF:USA 0IT:Germany

Address

65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5

Website

https://www.satellos.com

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines